Skip to main content
SpringerLink
Log in

Reirradiation of Recurrent and Second Primary Cancers of the Head and Neck: a Review of the Contemporary Evidence

  • Head and Neck Cancer (PL Swiecicki, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Recurrent and second primary head and neck cancers represent a clinical challenge due to frequently unresectable and/or locally advanced disease. Given that many of these patients have received definitive doses of radiation previously, reirradiation is associated with significant morbidity. Use of modern approaches such as conformal photon-based planning and charged particle therapy using protons or carbon ions allows for greater sparing of normal tissues while maintaining or escalating doses to tumor volumes. While the reirradiation data has consistently shown benefits to local control and even survival from escalation of radiotherapy dose, excessive cumulative doses can result in severe toxicities, including fatal carotid blowout syndrome. For all modalities, appropriate patient selection is of utmost importance. Large-scale trials and multi-institutional registry data are needed to standardize treatment modalities, and to determine optimal doses and volumes for reirradiation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.

    PubMed  Google Scholar 

  2. Ang KK, Zhang Q, Rosenthal DI, Nguyen-Tan PF, Sherman EJ, Weber RS, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(27):2940–50.

    CAS  Google Scholar 

  3. Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32(34):3858–66.

    CAS  Google Scholar 

  4. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(7):845–52.

    CAS  Google Scholar 

  5. Gillison ML, Trotti AM, Harris J, Eisbruch A, Harari PM, Adelstein DJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet (London, England). 2019;393(10166):40–50.

    CAS  Google Scholar 

  6. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.

    CAS  PubMed  Google Scholar 

  7. Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911. J Clin Oncol [Internet]. 2007;20;25(30):4800–5. Available from. https://doi.org/10.1200/JCO.2006.07.9194.

    Article  CAS  Google Scholar 

  8. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30(3):281–8.

    PubMed  Google Scholar 

  9. Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun R-J, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol [Internet]. 2008;1;26(34):5518–23. Available from. https://doi.org/10.1200/JCO.2007.15.0102.

    Article  CAS  Google Scholar 

  10. Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins LF, Triozzi P, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol [Internet]. 1992;1;10(8):1245–51. Available from. https://doi.org/10.1200/JCO.1992.10.8.1245.

    Article  Google Scholar 

  11. Jacobs C, Lyman G, Velez-García E, Sridhar KS, Knight W, Hochster H, et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol [Internet]. 1992;1;10(2):257–63. Available from. https://doi.org/10.1200/JCO.1992.10.2.257.

    Article  Google Scholar 

  12. Gibson MK, Li Y, Murphy B, Hussain MHA, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an Intergroup Trial of the Eastern Cooperative Oncology Group. J Clin Oncol [Internet]. 2005;20;23(15):3562–7. Available from. https://doi.org/10.1200/JCO.2005.01.057.

    Article  CAS  Google Scholar 

  13. Takiar V, Garden AS, Ma D, Morrison WH, Edson M, Zafereo ME, et al. Reirradiation of head and neck cancers with intensity modulated radiation therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys. 2016;95(4):1117–31.

    PubMed  Google Scholar 

  14. Lee J, Kim TH, Kim Y-S, Kim M, Park JW, Kim SH, et al. Intensity-modulated radiotherapy-based reirradiation for head and neck cancer: a Multi-institutional Study by Korean Radiation Oncology Group (KROG 1707). Cancer Res Treat. 2020;52(4):1031–40.

    PubMed  PubMed Central  Google Scholar 

  15. Diao K, Nguyen TP, Moreno AC, Reddy JP, Garden AS, Wang CH, et al. Stereotactic body ablative radiotherapy for reirradiation of small volume head and neck cancers is associated with prolonged survival: a large, single-institution, modern cohort study. Head Neck. 2021;

  16. Rühle A, Sprave T, Kalckreuth T, Stoian R, Haehl E, Zamboglou C, et al. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer. Radiat Oncol. 2020;15(1):81. https://doi.org/10.1186/s13014-020-01531-5.

  17. •• Ward MC, Riaz N, Caudell JJ, Dunlap NE, Isrow D, Zakem SJ, et al. Refining patient selection for reirradiation of head and neck squamous carcinoma in the IMRT Era: a multi-institution cohort study by the MIRI collaborative. Int J Radiat Oncol Biol Phys. 2018;100(3):586–94 This study is of outstanding importance as it is the largest multi-institutional joint effort on record in regard to reirradiation in RSPHNC. The recursive partitioning analysis presented by the authors has become an important framework for future study as well as patient prognostication in the treatment of this disease.

    PubMed  Google Scholar 

  18. Lee J, Shin I-S, Kim WC, Yoon WS, Koom WS, Rim CH. Reirradiation with intensity-modulated radiation therapy for recurrent or secondary head and neck cancer: meta-analysis and systematic review. Head Neck. 2020;42(9):2473–85.

    PubMed  Google Scholar 

  19. Bagley AF, Garden AS, Reddy JP, Moreno AC, Frank SJ, Rosenthal DI, et al. Highly conformal reirradiation in patients with prior oropharyngeal radiation: clinical efficacy and toxicity outcomes. Head Neck. 2020;42(11):3326–35.

    PubMed  PubMed Central  Google Scholar 

  20. • Vargo JA, Ward MC, Caudell JJ, Riaz N, Dunlap NE, Isrow D, et al. A multi-institutional comparison of SBRT and IMRT for definitive reirradiation of recurrent or second primary head and neck cancer. Int J Radiat Oncol Biol Phys. 2018;100(3):595–605 This study is of importance as it clearly outlines the role, safety, and efficacy of dose escalation to small volumes using SBRT.

    PubMed  Google Scholar 

  21. Orlandi E, Bonomo P, Ferella L, D’Angelo E, Maddalo M, Alterio D, et al. Long-term outcome of re-irradiation for recurrent or second primary head and neck cancer: a multi-institutional study of AIRO-Head and Neck working group. Head Neck. 2019;41(10):3684–92.

    PubMed  Google Scholar 

  22. Ansinelli H, Singh R, Sharma DL, Jenkins J, Davis J, Vargo JA, et al. Salvage stereotactic body radiation therapy for locally recurrent previously irradiated head and neck squamous cell carcinoma: an analysis from the RSSearch® Registry. Cureus. 2018;10(8):e3237.

    PubMed  PubMed Central  Google Scholar 

  23. Anand AK, Dua B, Bansal AK, Singh HM, Verma A, Kumar A. Stereotactic ablative radiotherapy (SABR) for recurrent and previously irradiated head and neck cancers. BJR open. 2020;2(1):20190051.

    PubMed  PubMed Central  Google Scholar 

  24. McDonald MW, Zolali-Meybodi O, Lehnert SJ, Estabrook NC, Liu Y, Cohen-Gadol AA, et al. Reirradiation of recurrent and second primary head and neck cancer with proton therapy. Int J Radiat Oncol Biol Phys. 2016;96(4):808–19.

    PubMed  Google Scholar 

  25. Phan J, Sio TT, Nguyen TP, Takiar V, Gunn GB, Garden AS, et al. Reirradiation of head and neck cancers with proton therapy: outcomes and analyses. Int J Radiat Oncol Biol Phys. 2016;96(1):30–41.

    PubMed  Google Scholar 

  26. Jiang P, Wang J, Ran W, Jiang Y, Tian S, Sun H. Five-year outcome of ultrasound-guided interstitial permanent (125)I seeds implantation for local head and neck recurrent tumors: a single center retrospective study. J Contemp Brachytherapy. 2019;11(1):28–34.

    PubMed  PubMed Central  Google Scholar 

  27. Khan N, Clemens M, Liu J, Garden AS, Lawyer A, Weber R, et al. The role of salvage surgery with interstitial brachytherapy for the management of regionally recurrent head and neck cancers. Cancers head neck. 2019;4:4.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Kharouta M, Zender C, Podder T, Rezaee R, Lavertu P, Fowler N, et al. Permanent interstitial Cesium-131 brachytherapy in treating high-risk recurrent head and neck cancer: a prospective pilot study. Front Oncol. 2021;11:639480.

    PubMed  PubMed Central  Google Scholar 

  29. Wald P, Grecula J, Walston S, Wei L, Bhatt A, Martin D, et al. Intraoperative electron beam radiotherapy for locoregionally persistent or recurrent head and neck cancer. Head Neck. 2019;41(7):2148–53.

    PubMed  Google Scholar 

  30. Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, et al. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. Int J Radiat Oncol Biol Phys. 2016;95(1):386–95.

    PubMed  PubMed Central  Google Scholar 

  31. Hayashi Y, Nakamura T, Mitsudo K, Kimura K, Yamaguchi H, Ono T, et al. Re-irradiation using proton beam therapy combined with weekly intra-arterial chemotherapy for recurrent oral cancer. Asia Pac J Clin Oncol. 2017;13(5):e394–401.

    PubMed  Google Scholar 

  32. Gordon K, Gulidov I, Semenov A, Golovanova O, Koryakin S, Makeenkova T, et al. Proton re-irradiation of unresectable recurrent head and neck cancers. Reports Pract Oncol Radiother J Gt Cancer Cent Pozn Polish Soc Radiat Oncol. 2021;26(2):203–10.

    Google Scholar 

  33. Yang J, Gao J, Wu X, Hu J, Hu W, Kong L, et al. Salvage carbon ion radiation therapy for locally recurrent or radiation-induced second primary sarcoma of the head and neck. J Cancer. 2018;9(12):2215–23.

    PubMed  PubMed Central  Google Scholar 

  34. •• Held T, Windisch P, Akbaba S, Lang K, El Shafie R, Bernhardt D, et al. Carbon ion reirradiation for recurrent head and neck cancer: a single-institutional experience. Int J Radiat Oncol Biol Phys. 2019;105(4):803–11 This study is of outstanding importance given the large dataset provided within the context of a paucity of CIRT data in the literature.

    CAS  PubMed  Google Scholar 

  35. Vischioni B, Dhanireddy B, Severo C, Bonora M, Ronchi S, Vitolo V, et al. Reirradiation of salivary gland tumors with carbon ion radiotherapy at CNAO. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;145:172–7.

    CAS  Google Scholar 

  36. Hegde JV, Demanes DJ, Veruttipong D, Chin RK, Park S-J, Kamrava M. Head and neck cancer reirradiation with interstitial high-dose-rate brachytherapy. Head Neck. 2018;40(7):1524–33.

    PubMed  Google Scholar 

  37. Breen W, Kelly J, Park HS, Son Y, Sasaki C, Wilson L, et al. Permanent interstitial brachytherapy for previously irradiated head and neck cancer. Cureus. 2018;10(4):e2517.

    PubMed  PubMed Central  Google Scholar 

  38. Lomax AJ. Charged particle therapy: the physics of interaction. Cancer J. 2009;15(4):285–91.

    PubMed  Google Scholar 

  39. Yoo GS. Yu J Il, Cho S, Jung SH, Han Y, Park S, et al. Comparison of clinical outcomes between passive scattering versus pencil-beam scanning proton beam therapy for hepatocellular carcinoma. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2020;146:187–93.

    CAS  Google Scholar 

  40. Chuong M, Badiyan SN, Yam M, Li Z, Langen K, Regine W, et al. Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. J Gastrointest Oncol. 2018;9(4):687–93.

    PubMed  PubMed Central  Google Scholar 

  41. Uhl M, Herfarth K, Debus J. Comparing the use of protons and carbon ions for treatment. Cancer J. 2014;20(6):433–9.

    CAS  PubMed  Google Scholar 

  42. Particle therapy facilities in clinical operation [Internet]. Particle Therapy Co-Operative Group. Available from: https://www.ptcog.ch/index.php/facilities-in-operation

  43. Dionisi F, Fiorica F, D’Angelo E, Maddalo M, Giacomelli I, Tornari E, et al. Organs at risk’s tolerance and dose limits for head and neck cancer re-irradiation: a literature review. Oral Oncol. 2019;98:35–47.

    CAS  PubMed  Google Scholar 

  44. Alterio D, Turturici I, Volpe S, Ferrari A, Russell-Edu SW, Vischioni B, et al. Carotid blowout syndrome after reirradiation for head and neck malignancies: a comprehensive systematic review for a pragmatic multidisciplinary approach. Crit Rev Oncol Hematol. 2020;155:103088.

    PubMed  Google Scholar 

  45. Embring A, Onjukka E, Mercke C, Lax I, Berglund A, Bornedal S, et al. Re-irradiation for head and neck cancer: cumulative dose to organs at risk and late side effects. Cancers (Basel). 2021;13(13):3173. https://doi.org/10.3390/cancers13133173.

  46. Bots WTC, van den Bosch S, Zwijnenburg EM, Dijkema T, van den Broek GB, Weijs WLJ, et al. Reirradiation of head and neck cancer: long-term disease control and toxicity. Head Neck. 2017;39(6):1122–30.

    PubMed  PubMed Central  Google Scholar 

  47. Garg S, Kilburn JM, Lucas JT Jr, Randolph D, Urbanic JJ, Hinson WH, et al. Reirradiation for second primary or recurrent cancers of the head and neck: dosimetric and outcome analysis. Head Neck [Internet]. 2016;1;38(S1):E961–9. Available from. https://doi.org/10.1002/hed.24136.

    Article  Google Scholar 

  48. •• Grimm J, Vargo JA, Mavroidis P, Moiseenko V, Emami B, Jain S, et al. Initial data pooling for radiation dose-volume tolerance for carotid artery blowout and other bleeding events in hypofractionated head and neck retreatments. Int J Radiat Oncol Biol Phys. 2021;110(1):147–59 This study is of outstanding importance given the impressive modeling work performed in order to accurately describe risks of hemorrhage events associated with reirradiation of the head and neck. Especially as the use of SBRT becomes more common in the treatment of these patients, the models presented here fulfill a previously unmet need for accurate toxicity risk assessment.

    PubMed  Google Scholar 

  49. Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro GJ, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet (London, England). 2019;394(10212):1915–28.

    CAS  Google Scholar 

  50. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncol [Internet]. 2018;81:45–51 Available from: https://www.sciencedirect.com/science/article/pii/S1368837518301490.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Wong S, Torres-Saavedra P, Le QT, Chung C, Jang S, Huq MS, et al. Safety of reRT with SBRT plus concurrent and adjuvant pembrolizumab in patients with recurrent or new second primary head and neck squamous cell cancer in a previously irradiated field: RTOG 3507 Foundation (KEYSTROKE). Int J Radiat Oncol [Internet]. 2020;106(5):1224–5 Available from: https://www.sciencedirect.com/science/article/pii/S0360301620301760.

    Google Scholar 

Download references

Funding

V.T. acknowledges support from the United States Department of Veterans Affairs Biomedical Laboratory Research and Development Service [IK2 BX004360].

Author information

Authors and Affiliations

  1. University of Cincinnati Departments of Radiation Oncology, Cincinnati, OH, USA

    Paul J. Kreinbrink MD, Luke M. Lewis MD, Kevin P. Redmond MD & Vinita Takiar MD, PhD

  2. Cincinnati VA Medical Center, Cincinnati, OH, USA

    Vinita Takiar MD, PhD

  3. University of Cincinnati Medical Center, 234 Goodman Street, ML 0757, Cincinnati, OH, 45267, USA

    Vinita Takiar MD, PhD

Authors
  1. Paul J. Kreinbrink MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luke M. Lewis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kevin P. Redmond MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Vinita Takiar MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vinita Takiar MD, PhD.

Ethics declarations

Conflict of Interest

Paul J. Kreinbrink declares that he has no conflict of interest. Luke M. Lewis declares that he has no conflict of interest. Kevin P. Redmond declares that he has no conflict of interest. Vinita Takiar has received research funding from Merck, and has received an honorarium for participating in a National Institutes of Health (NIH) Study Section.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Head and Neck Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kreinbrink, P.J., Lewis, L.M., Redmond, K.P. et al. Reirradiation of Recurrent and Second Primary Cancers of the Head and Neck: a Review of the Contemporary Evidence. Curr. Treat. Options in Oncol. 23, 295–310 (2022). https://doi.org/10.1007/s11864-021-00936-y

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-021-00936-y

Keywords

Search

Navigation